|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 172.97 USD | -2.34% |
|
-2.46% | -1.72% |
| 04-07 | Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update | DJ |
| 04-07 | RBC Capital Adjusts Biogen Price Target to $213 From $233, Maintains Outperform Rating | MT |
| Capitalization | 25.38B 21.63B 20.01B 18.84B 35.1B 2,361B 35.82B 235B 91.87B 1,134B 95.26B 93.24B 4,039B | P/E ratio 2026 * |
14.6x | P/E ratio 2027 * | 13.6x |
|---|---|---|---|---|---|
| Enterprise value | 25.74B 21.93B 20.29B 19.11B 35.59B 2,394B 36.32B 238B 93.15B 1,150B 96.6B 94.55B 4,096B | EV / Sales 2026 * |
2.73x | EV / Sales 2027 * | 2.44x |
| Free-Float |
85.5% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biogen Inc.
| 1 day | -2.34% | ||
| 1 week | -2.46% | ||
| Current month | -5.65% | ||
| 1 month | -9.19% | ||
| 3 months | -7.81% | ||
| 6 months | +18.01% | ||
| Current year | -1.72% |
| 1 week | 168.64 |  | 180.24 |
| 1 month | 168.64 | | 192.28 |
| Current year | 160.36 | | 202.41 |
| 1 year | 114.66 | | 202.41 |
| 3 years | 110.04 | | 319.76 |
| 5 years | 110.04 | | 468.55 |
| 10 years | 110.04 | | 468.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 14/11/2022 | |
Robin Kramer
DFI | Director of Finance/CFO | 60 | 01/03/2025 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 59 | 02/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Caroline Dorsa
CHM | Chairman | 66 | 26/06/2023 |
Eric Rowinsky
BRD | Director/Board Member | 69 | 23/03/2010 |
Stephen Sherwin
BRD | Director/Board Member | 77 | 01/01/2010 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 4.3% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.34% | -2.46% | +50.19% | -39.03% | 25.38B | |
| -2.47% | -1.70% | +35.13% | -8.63% | 76.85B | |
| +1.18% | +3.97% | +105.99% | +221.41% | 61.45B | |
| -0.57% | +57.10% | +57.10% | +57.10% | 49.05B | |
| -0.74% | +0.19% | -40.28% | -53.87% | 47.32B | |
| -0.62% | +3.58% | +94.50% | -67.18% | 20.21B | |
| +0.85% | -3.28% | +85.34% | +124.05% | 19.61B | |
| -0.92% | +0.15% | +68.93% | +29.53% | 19.12B | |
| +1.04% | +1.35% | +59.80% | +53.28% | 15.18B | |
| -1.23% | +1.97% | +119.96% | +385.61% | 14.46B | |
| Average | -0.58% | +0.82% | +63.67% | +70.23% | 34.86B | |
| Weighted average by Cap. | -0.73% | +1.09% | +54.28% | +58.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.42B 8.02B 7.42B 6.99B 13.02B 876B 13.29B 87.1B 34.08B 421B 35.34B 34.59B 1,499B | 9.35B 7.97B 7.37B 6.94B 12.93B 870B 13.19B 86.48B 33.84B 418B 35.09B 34.35B 1,488B |
| Net income | 1.85B 1.58B 1.46B 1.38B 2.56B 172B 2.62B 17.14B 6.71B 82.77B 6.96B 6.81B 295B | 2.01B 1.71B 1.58B 1.49B 2.77B 187B 2.83B 18.55B 7.26B 89.59B 7.53B 7.37B 319B |
| Net Debt | 356M 303M 281M 264M 492M 33.09B 502M 3.29B 1.29B 15.89B 1.34B 1.31B 56.62B | -2.57B -2.19B -2.03B -1.91B -3.56B -239B -3.63B -23.78B -9.3B -115B -9.65B -9.44B -409B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/04/26 | 172.97 $ | -2.34% | 1,501,979 |
| 09/04/26 | 177.11 $ | -1.55% | 1,266,491 |
| 08/04/26 | 179.90 $ | +2.44% | 1,289,686 |
| 07/04/26 | 175.61 $ | +1.90% | 1,515,806 |
| 06/04/26 | 172.34 $ | -2.82% | 2,149,104 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition